Skip to main content
UniHealth

Doctor search

Roberto A Novoa, MD

Dermatology · Stanford

NPI 1326272089

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Offices
4

Offices

4 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Novoa’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A131200 · Current

Licensed to practise in California · since 2014 · expires 2027-12-31 · Harvard Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$208,201

Medicare paid this office $208,201 for 2,274 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Pathology examination of tissue using a microscope, intermediate complexity1,827$93,618$32
Special stained specimen slides to examine tissue, each additional procedure306$18,104$25
Special stained specimen slides to examine tissue, initial procedure419$17,438$30
Surgical pathology consultation and report on referred slides prepared elsewhere170$13,030$70
Special stained specimen slides to identify organisms including interpretation and report296$11,698$23
See all 23 services
Every Original Medicare service billed
Pathology examination of tissue using a microscope, intermediate complexity1,827$93,618$32
Special stained specimen slides to examine tissue, each additional procedure306$18,104$25
Special stained specimen slides to examine tissue, initial procedure419$17,438$30
Surgical pathology consultation and report on referred slides prepared elsewhere170$13,030$70
Special stained specimen slides to identify organisms including interpretation and report296$11,698$23
Return visit (30+ min)88$10,196$80
Microscopic genetic analysis of tumor, manual72$9,380$36
Antibody evaluation, each additional single antibody stain procedure61$6,747$26
Short return visit (20+ min)71$3,947$48
Pathology examination of tissue using a microscope, moderately high complexity36$3,430$73
New patient visit (30+ min)40$2,710$68
Destruction of precancer skin growth, 1 growth44$2,573$49
Antibody evaluation, initial single antibody stain procedure61$2,065$32
Surgical pathology consultation and report on referred material requiring preparation of slides20$1,609$77
Pathology examination of tissue using a microscope, moderately low complexity153$1,587$10
Biopsy of related skin growth, first growth49$1,340$25
Return visit (30+ min)13$1,207$93
Genetic sequencing localization, initial procedure20$924$38
Genetic sequencing localization, each additional procedure12$636$30
New patient visit (15+ min)19$596$31
Biopsy of related skin growth, each additional growth19$440$18
Special stained specimen slides to examine tissue including interpretation and report22$301$11
Destruction of precancer skin growth, 2-14 growths33$207$2

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions240More than 81% of doctors who do this
Skin biopsy124More than 78% of doctors who do this

Who their Medicare patients are

2,274 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 17% · Women 45% · Also on Medicaid 12% · Health risk score 1.39. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 67% · Coronary heart disease 26% · Chronic kidney disease 24% · Diabetes 21% · Cancer 20% · Atrial fibrillation 20% · Heart failure 15% · Depression 15% · COPD 10% · Stroke 8% · Dementia 6%.

The office billed $2,515,593, Medicare allowed $274,498 and paid $208,201; for 6,431 services of 37 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242,2746,431761.39$2,515,593$208,201
20232,1175,995761.36$2,092,986$194,300
20221,8755,258761.32$1,508,483$174,006
20211,7984,963761.38$963,849$167,674
20201,3634,125751.45$788,041$140,963
20191,6704,990751.44$880,532$167,638
20181,5434,216751.40$734,645$141,517
20171,3103,480751.39$614,038$119,252
20161,0372,671751.43$465,333$91,823
20151,1343,104751.27$543,336$106,228
2014277616731.34$103,695$19,439

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 22 services

Original Medicare services billed in 2023
Pathology examination of tissue using a microscope, intermediate complexity1,698$90,676$32
Special stained specimen slides to examine tissue, initial procedure388$16,712$31
Special stained specimen slides to examine tissue, each additional procedure277$16,210$26
Surgical pathology consultation and report on referred slides prepared elsewhere176$14,289$75
Special stained specimen slides to identify organisms including interpretation and report261$11,454$24
Microscopic genetic analysis of tumor, manual52$7,235$39
Return visit (30+ min)68$6,981$78
Antibody evaluation, each additional single antibody stain procedure57$6,273$26
Short return visit (20+ min)61$4,064$53
Destruction of precancer skin growth, 1 growth50$2,855$47
Pathology examination of tissue using a microscope, moderately high complexity19$2,464$77
New patient visit (30+ min)34$2,348$69
Antibody evaluation, initial single antibody stain procedure57$2,032$33
Surgical pathology consultation and report on referred material requiring preparation of slides20$1,713$82
Pathology examination of tissue using a microscope, moderately low complexity129$1,441$10
Biopsy of related skin growth, first growth35$1,046$26
Genetic sequencing localization, initial procedure20$804$38
New patient visit (15+ min)15$554$37
Punch biopsy, first skin growth11$479$40
Biopsy of related skin growth, each additional growth12$425$20
Special stained specimen slides to examine tissue including interpretation and report19$278$11
Destruction of precancer skin growth, 2-14 growths39$237$2

2022: 22 services

Original Medicare services billed in 2022
Pathology examination of tissue using a microscope, intermediate complexity1,558$84,245$34
Special stained specimen slides to examine tissue, each additional procedure227$17,841$26
Special stained specimen slides to examine tissue, initial procedure317$13,455$32
Special stained specimen slides to identify organisms including interpretation and report201$8,730$24
Surgical pathology consultation and report on referred slides prepared elsewhere95$7,604$78
Antibody evaluation, each additional single antibody stain procedure55$6,368$27
Return visit (30+ min)54$6,015$79
Microscopic genetic analysis of tumor, manual38$5,329$39
Short return visit (20+ min)62$3,735$49
Pathology examination of tissue using a microscope, moderately high complexity23$3,172$77
Surgical pathology consultation and report on referred material requiring preparation of slides32$2,517$79
Destruction of precancer skin growth, 1 growth48$2,384$40
Antibody evaluation, initial single antibody stain procedure55$2,021$34
New patient visit (30+ min)23$1,634$71
Pathology examination of tissue using a microscope, moderately low complexity91$979$10
Genetic sequencing localization, initial procedure21$937$41
Biopsy of related skin growth, first growth30$779$24
New patient visit (15+ min)15$493$33
Short return visit14$432$27
Punch biopsy, first skin growth13$374$29
Special stained specimen slides to examine tissue including interpretation and report16$270$11
Destruction of precancer skin growth, 2-14 growths28$207$2

2021: 22 services

Original Medicare services billed in 2021
Pathology examination of tissue using a microscope, intermediate complexity1,480$80,642$33
Special stained specimen slides to examine tissue, each additional procedure196$13,643$27
Special stained specimen slides to examine tissue, initial procedure300$13,277$33
Surgical pathology consultation and report on referred slides prepared elsewhere138$10,764$76
Special stained specimen slides to identify organisms including interpretation and report210$8,813$25
Antibody evaluation, each additional single antibody stain procedure51$5,597$27
Short return visit (20+ min)77$5,127$54
Return visit (30+ min)38$4,661$88
Microscopic genetic analysis of tumor, manual36$4,366$40
Pathology examination of tissue using a microscope, moderately high complexity27$3,568$79
Destruction of precancer skin growth, 1 growth50$3,000$48
Surgical pathology consultation and report on referred material requiring preparation of slides31$2,725$83
Antibody evaluation, initial single antibody stain procedure51$1,887$33
Biopsy of related skin growth, first growth41$1,151$26
New patient visit (30+ min)14$986$70
Pathology examination of tissue using a microscope, moderately low complexity90$984$10
Genetic sequencing localization, initial procedure14$622$41
Biopsy of related skin growth, each additional growth14$458$18
Short return visit16$433$27
New patient visit (15+ min)12$412$34
Special stained specimen slides to examine tissue including interpretation and report17$275$11
Destruction of precancer skin growth, 2-14 growths38$251$2

2020: 25 services

Original Medicare services billed in 2020
Pathology examination of tissue using a microscope, intermediate complexity1,068$60,683$35
Special stained specimen slides to examine tissue, initial procedure297$13,283$34
Special stained specimen slides to examine tissue, each additional procedure168$11,867$27
Surgical pathology consultation and report on referred slides prepared elsewhere100$8,389$78
Special stained specimen slides to identify organisms including interpretation and report174$8,164$26
Antibody evaluation, each additional single antibody stain procedure63$6,935$28
Microscopic genetic analysis of tumor, manual46$6,933$41
Return visit (30+ min)57$3,894$63
Surgical pathology consultation and report on referred material requiring preparation of slides33$2,830$83
Antibody evaluation, initial single antibody stain procedure63$2,250$35
Return visit (30+ min)25$1,893$73
Pathology examination of tissue using a microscope, moderately high complexity17$1,840$80
Short return visit (20+ min)35$1,602$43
Destruction of precancer skin growth, 1 growth33$1,430$42
Destruction of precancer skin growth, 1 growth16$828$52
Short return visit (20+ min)22$786$36
Pathology examination of tissue using a microscope, moderately low complexity55$596$10
Genetic sequencing localization, initial procedure11$559$43
Biopsy of related skin growth, first growth23$538$22
New patient visit (15+ min)12$509$42
Biopsy of related skin growth, first growth17$478$28
Special stained specimen slides to examine tissue including interpretation and report16$377$12
Short return visit11$327$23
Destruction of precancer skin growth, 2-14 growths25$133$2
Destruction of precancer skin growth, 2-14 growths12$77$2

2019: 21 services

Original Medicare services billed in 2019
Pathology examination of tissue using a microscope, intermediate complexity1,353$76,517$34
Special stained specimen slides to examine tissue, each additional procedure173$14,697$27
Special stained specimen slides to examine tissue, initial procedure317$14,396$33
Special stained specimen slides to identify organisms including interpretation and report238$11,306$24
Surgical pathology consultation and report on referred slides prepared elsewhere125$10,011$75
Return visit (30+ min)85$8,965$66
Antibody evaluation, each additional single antibody stain procedure56$6,293$27
Microscopic genetic analysis of tumor, manual46$4,100$41
Surgical pathology consultation and report on referred material requiring preparation of slides42$3,620$82
Destruction of precancer skin growth, 1 growth49$2,989$45
Pathology examination of tissue using a microscope, moderately high complexity21$2,403$78
Antibody evaluation, initial single antibody stain procedure59$2,171$34
New patient visit (30+ min)28$1,714$61
Biopsy of related skin growth, first growth38$1,144$27
Pathology examination of tissue using a microscope, moderately low complexity75$899$10
Genetic sequencing localization, initial procedure20$880$40
New patient visit (15+ min)16$605$38
Short return visit (20+ min)11$604$46
Genetic sequencing localization, each additional procedure12$513$29
Destruction of precancer skin growth, 2-14 growths39$343$2
Special stained specimen slides to examine tissue including interpretation and report20$286$10

2018: 23 services

Original Medicare services billed in 2018
Pathology examination of tissue using a microscope, intermediate complexity1,235$68,662$33
Special stained specimen slides to examine tissue, initial procedure277$11,123$32
Surgical pathology consultation and report on referred slides prepared elsewhere127$9,806$74
Special stained specimen slides to examine tissue, each additional procedure133$9,720$26
Special stained specimen slides to identify organisms including interpretation and report166$8,643$24
Return visit (30+ min)79$6,244$60
Antibody evaluation, each additional single antibody stain procedure39$4,241$26
Surgical pathology consultation and report on referred material requiring preparation of slides36$2,872$80
Pathology examination of tissue using a microscope, moderately high complexity16$2,638$78
Return visit (30+ min)33$2,330$69
Destruction of precancer skin growth, 1 growth36$1,945$43
Microscopic genetic analysis of tumor, manual25$1,861$41
Antibody evaluation, initial single antibody stain procedure41$1,427$32
New patient visit (30+ min)22$1,409$64
Biopsy of single growth of skin and/or tissue38$1,207$29
Destruction of precancer skin growth, 1 growth18$888$49
Pathology examination of tissue using a microscope, moderately low complexity67$690$10
Genetic sequencing localization, initial procedure12$489$41
New patient visit (15+ min)11$484$44
Biopsy of single growth of skin and/or tissue12$434$36
Biopsy of each additional growth of skin and/or tissue13$397$21
Destruction of precancer skin growth, 2-14 growths33$162$2
Destruction of precancer skin growth, 2-14 growths14$93$2

2017: 20 services

Original Medicare services billed in 2017
Pathology examination of tissue using a microscope, intermediate complexity1,045$56,937$34
Special stained specimen slides to examine tissue, initial procedure266$11,203$32
Special stained specimen slides to examine tissue, each additional procedure119$9,161$26
Special stained specimen slides to identify organisms including interpretation and report150$6,788$25
Surgical pathology consultation and report on referred slides prepared elsewhere86$6,544$75
Return visit (30+ min)62$5,678$59
Surgical pathology consultation and report on referred material requiring preparation of slides44$3,483$79
Antibody evaluation, each additional single antibody stain procedure33$3,333$26
Pathology examination of tissue using a microscope, moderately high complexity15$2,957$78
Destruction of precancer skin growth, 1 growth34$2,122$43
New patient visit (30+ min)33$2,041$62
Microscopic genetic analysis of tumor, manual17$1,718$51
Antibody evaluation, initial single antibody stain procedure33$1,138$33
Biopsy of single growth of skin and/or tissue37$1,131$28
Pathology examination of tissue using a microscope, moderately low complexity52$598$10
Short return visit (20+ min)13$576$44
New patient visit (15+ min)15$571$38
Biopsy of each additional growth of skin and/or tissue12$337$20
Special stained specimen slides to examine tissue including interpretation and report16$197$11
Destruction of precancer skin growth, 2-14 growths25$146$2

2016: 18 services

Original Medicare services billed in 2016
Pathology examination of tissue using a microscope, intermediate complexity789$40,146$33
Surgical pathology consultation and report on referred slides prepared elsewhere96$7,633$78
Special stained specimen slides to examine tissue, initial procedure171$6,832$32
Special stained specimen slides to examine tissue, each additional procedure68$6,166$25
Return visit (30+ min)61$5,953$64
Special stained specimen slides to identify organisms including interpretation and report130$4,784$24
Antibody evaluation, each additional single antibody stain procedure26$2,721$25
Surgical pathology consultation and report on referred material requiring preparation of slides32$2,507$78
New patient visit (30+ min)38$2,290$60
Destruction of precancer skin growth, 1 growth33$2,256$48
Microscopic genetic analysis of tumor, manual25$1,844$51
Biopsy of single growth of skin and/or tissue36$1,473$32
Antibody evaluation, initial single antibody stain procedure27$1,002$33
Short return visit (20+ min)18$866$43
New patient visit (15+ min)16$717$45
Pathology examination of tissue using a microscope, moderately low complexity52$546$9
Biopsy of each additional growth of skin and/or tissue13$363$23
Destruction of precancer skin growth, 2-14 growths27$167$2

2015: 20 services

Original Medicare services billed in 2015
Pathology examination of tissue using a microscope, intermediate complexity858$46,005$34
Surgical pathology consultation and report on referred slides prepared elsewhere125$9,536$73
Special stained specimen slides to examine tissue, initial procedure215$8,512$32
Special stained specimen slides to identify organisms including interpretation and report171$6,855$25
Special stained specimen slides to examine tissue, each additional procedure92$6,828$20
Antibody evaluation, initial single antibody stain procedure28$6,030$39
Surgical pathology consultation and report on referred material requiring preparation of slides43$3,251$74
New patient visit (30+ min)49$3,087$63
Return visit (30+ min)26$2,291$67
Microscopic genetic analysis of tumor, manual25$2,218$50
Biopsy of single growth of skin and/or tissue41$1,610$34
Destruction of precancer skin growth, 1 growth27$1,565$45
Short return visit (20+ min)19$829$41
Genetic sequencing localization, initial procedure14$691$41
Pathology examination of tissue using a microscope, moderately low complexity62$671$10
New patient visit (15+ min)16$627$39
Short return visit17$477$23
Special stained specimen slides to examine tissue including interpretation and report20$260$11
Biopsy of each additional growth of skin and/or tissue11$248$23
Destruction of precancer skin growth, 2-14 growths21$122$2

2014: 6 services

Original Medicare services billed in 2014
Pathology examination of tissue using a microscope, intermediate complexity232$11,818$34
Special stained specimen slides to identify organisms including interpretation and report47$1,739$25
Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain52$1,598$28
Surgical pathology consultation and report on referred slides prepared elsewhere14$1,142$76
Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)28$639$11
Pathology examination of tissue using a microscope, moderately low complexity21$232$10

Medicaid work

$31,725 in 2024

Medicaid paid $31,725 for 880 billed services this clinician did in 2024, up to 88 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
TISSUE EXAM BY PATHOLOGIST568$20,672
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)185$5,613
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure85$4,327
IMHCHEM/IMCYTCHM EA ADD ANTB22$743
TISSUE EXAM BY PATHOLOGIST20$370
Medicaid work by year
2024880588$31,725
2023939588$33,760
2022462351$16,294
2021519347$17,995
2020304339$11,429
2019406345$12,912
2018332239$12,919
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
TISSUE EXAM BY PATHOLOGIST588$22,747
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)159$4,997
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure108$3,867
TISSUE EXAM BY PATHOLOGIST44$1,156
IMHCHEM/IMCYTCHM EA ADD ANTB40$993

2022

Largest Medicaid services in 2022
TISSUE EXAM BY PATHOLOGIST373$12,967
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)55$1,980
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure34$1,348

2021

Largest Medicaid services in 2021
TISSUE EXAM BY PATHOLOGIST394$13,110
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)107$4,257
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure18$628

2020

Largest Medicaid services in 2020
TISSUE EXAM BY PATHOLOGIST253$9,102
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)38$1,992
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure13$335

2019

Largest Medicaid services in 2019
TISSUE EXAM BY PATHOLOGIST355$11,239
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure25$921
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)26$753

2018

Largest Medicaid services in 2018
TISSUE EXAM BY PATHOLOGIST308$11,741
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)24$1,178

Drugs they prescribed that Part D paid

$164,586

Pharmacies billed $164,586 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 367) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

334 generic and 33 brand-name prescriptions · $164,586 in drug cost · 16 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Tacrolimus16$2,926$183
Clobetasol Propionate24$1,320$55
Calcipotriene12$1,282$107
Desonide16$1,204$75
Fluorouracil14$1,009$72
See all 11 drugs
Every Part D drug this clinician prescribed
Tacrolimus16$2,926$183
Clobetasol Propionate24$1,320$55
Calcipotriene12$1,282$107
Desonide16$1,204$75
Fluorouracil14$1,009$72
Doxycycline Hyclate12$970$81
Fluocinonide24$854$36
Metronidazole18$843$47
Ketoconazole52$647$12
Minoxidil25$381$15
Triamcinolone Acetonide26$202$8

Year by year

Part D prescribing by year
2024367990% (0)9%$164,586
2023297880% (0)None$140,883
2022335780% (0)10%$91,398
2021307830% (0)10%$129,535
2020218720% (0)10%$40,671
2019167550% (0)12%$9,916
2018198640% (0)8%$22,591
2017146540% (0)12%$11,773
2016162550% (0)17%$15,945
20159636None23%$7,849

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 9 drugs

Part D drugs prescribed in 2023
Fluocinonide34$1,895$56
Clobetasol Propionate16$1,666$104
Tacrolimus11$1,086$99
Doxycycline Hyclate11$1,001$91
Desonide11$896$81
Ketoconazole42$812$19
Clotrimazole17$244$14
Triamcinolone Acetonide20$220$11
Hydrocortisone14$78$6

2022: 11 drugs

Part D drugs prescribed in 2022
Jublia11$8,026$730
Fluocinonide44$2,694$61
Calcipotriene14$2,043$146
Fluorouracil13$1,450$112
Ketoconazole53$1,097$21
Ciclopirox14$1,061$76
Desonide13$1,032$79
Clotrimazole22$520$24
Triamcinolone Acetonide25$319$13
Mupirocin13$259$20
Gabapentin20$170$8

2021: 10 drugs

Part D drugs prescribed in 2021
Fluocinonide39$2,143$55
Calcipotriene13$1,944$150
Clobetasol Propionate15$1,371$91
Ketoconazole48$848$18
Ciclopirox11$355$32
Mupirocin13$227$17
Triamcinolone Acetonide21$185$9
Gabapentin16$185$12
Clotrimazole14$139$10
Hydrocortisone20$85$4

2020: 5 drugs

Part D drugs prescribed in 2020
Fluorouracil18$1,831$102
Clobetasol Propionate16$1,826$114
Fluocinonide30$1,526$51
Ketoconazole29$448$15
Triamcinolone Acetonide22$262$12

2019: 5 drugs

Part D drugs prescribed in 2019
Clobetasol Propionate12$1,998$166
Fluocinonide15$615$41
Ketoconazole19$454$24
Triamcinolone Acetonide25$222$9
Nystatin11$138$13

2018: 4 drugs

Part D drugs prescribed in 2018
Ketoconazole24$1,368$57
Fluocinonide22$1,045$48
Clotrimazole21$508$24
Triamcinolone Acetonide15$283$19

2017: 3 drugs

Part D drugs prescribed in 2017
Doxycycline Hyclate15$2,122$141
Desonide23$1,669$73
Triamcinolone Acetonide12$130$11

2016: 4 drugs

Part D drugs prescribed in 2016
Desonide22$3,593$163
Fluocinonide15$1,074$72
Ketoconazole28$809$29
Triamcinolone Acetonide18$243$13

2015: 2 drugs

Part D drugs prescribed in 2015
Triamcinolone Acetonide16$354$22
Ketoconazole15$194$13

Money from drug and device companies

$31 in 2023

Industry payments by year
202312None$31
202011$2,400$2,400

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerCibinqo$31
2 payments
  • Education for Cibinqo · 2023-05-10 · $15
  • Education for Cibinqo · 2023-04-12 · $15
See all 2 published payments
Every published payment
PfizerEducation · 2023-05-10Cibinqo$15
PfizerEducation · 2023-04-12Cibinqo$15
See earlier years (2020)

2020: $2,400

Payments by company in 2020
Stemline TherapeuticsElzonris$2,400
1 payment
  • Honoraria for Elzonris · 2020-03-10 · $2,400

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1326272089
Licence
CA A131200California A131200: Current · expires 2027-12-31
Trained
Harvard Medical School, 2009
Gender
Male
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2009-05-11
NPI last updated
2024-03-14
NPI record certified
2024-03-14

This is when the NPI record was last certified, not a medical board exam.